The Interplay Between Accumulation of Amyloid-Beta and Tau Proteins, PANoptosis, and Inflammation in Alzheimer’s Disease

被引:1
|
作者
Xianbo Zhuang [1 ]
Jie Lin [2 ]
Yamin Song [3 ]
Ru Ban [1 ]
Xin Zhao [1 ]
Zhangyong Xia [1 ]
Zheng Wang [1 ]
Guifeng Zhang [4 ]
机构
[1] Department of Neurology, Liaocheng People’s Hospital and Liaocheng Hospital Affiliated to Shandong First Medical University, Liaocheng
[2] School of Basic Medicine Sciences, Shandong University, Jinan
[3] Department of Joint Laboratory for Translational Medicine Research, Liaocheng People’s Hospital, Liaocheng
[4] Department of Neurology, Liaocheng People’s Hospital, Shandong University, Jinan
[5] Department of Neurology, the Second People’s Hospital of Liaocheng, Liaocheng
[6] Department of Neurosurgery, Liaocheng Traditional Chinese Medicine Hospital, Liaocheng
关键词
Alzheimer’s disease; Amyloid-beta; Inflammation; PANoptosis; Tau protein; Therapeutic strategy;
D O I
10.1007/s12017-024-08815-z
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is a common progressive neurodegenerative disorder, and the vast majority of cases occur in elderly patients. Recently, the accumulation of Aβ and tau proteins has drawn considerable attention in AD research. This review explores the multifaceted interactions between these proteins and their contribution to the pathological landscape of AD, encompassing synaptic dysfunction, neuroinflammation, and PANoptosis. PANoptosis is a collective term for programmed cell death (PCD) modalities that encompass elements of apoptosis, pyroptosis, and necroptosis. The accumulation of Aβ peptides and tau proteins, along with the immune response in brain cells, may trigger PANoptosis, thus advancing the progression of the disease. Recent advancements in molecular imaging and genetics have provided deeper insights into the interactions between Aβ peptides, tau proteins, and the immune response. The review also discusses the role of mitochondrial dysregulation in AD. The exploration of the interplay between neurodegeneration, immune responses, and cell death offers promising avenues for the development of innovative treatments. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
引用
收藏
相关论文
共 50 条
  • [41] Association of Hippocampal Subfield Volumes with Amyloid-Beta Deposition in Alzheimer's Disease
    Baek, Min Seok
    Lee, Narae
    Kim, Jin Woo
    Hong, Jin Yong
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
  • [42] Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease
    Reda, Sherif M.
    Setti, Sharay E.
    Berthiaume, Andree-Anne
    Wu, Wei
    Taylor, Robert W.
    Johnston, Jewel L.
    Stein, Liana R.
    Moebius, Hans J.
    Church, Kevin J.
    NEUROTHERAPEUTICS, 2024, 21 (04)
  • [43] Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease
    Dorey, Evan
    Chang, Nina
    Liu, Qing Yan
    Yang, Ze
    Zhang, Wandong
    NEUROSCIENCE BULLETIN, 2014, 30 (02) : 317 - 330
  • [44] Soluble amyloid-beta isoforms predict downstream Alzheimer's disease pathology
    Povala, Guilherme
    Bellaver, Bruna
    De Bastiani, Marco Antonio
    Brum, Wagner S.
    Ferreira, Pamela C. L.
    Bieger, Andrei
    Pascoal, Tharick A.
    Benedet, Andrea L.
    Souza, Diogo O.
    Araujo, Ricardo M.
    Zatt, Bruno
    Rosa-Neto, Pedro
    Zimmer, Eduardo R.
    CELL AND BIOSCIENCE, 2021, 11 (01)
  • [45] Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy
    Xin, Shu-Hui
    Tan, Lin
    Cao, Xipeng
    Yu, Jin-Tai
    Tan, Lan
    NEUROTOXICITY RESEARCH, 2018, 34 (03) : 733 - 748
  • [46] Clearance of Amyloid Beta and Tau in Alzheimer’s Disease: from Mechanisms to Therapy
    Shu-Hui Xin
    Lin Tan
    Xipeng Cao
    Jin-Tai Yu
    Lan Tan
    Neurotoxicity Research, 2018, 34 : 733 - 748
  • [47] Alzheimer's disease:: relationship between muscarinic cholinergic receptors, β-amyloid and tau proteins
    Pavía, J
    de Ceballos, ML
    de la Cuesta, FS
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1998, 12 (05) : 473 - 481
  • [48] The Alzheimer's Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease JACC Focus Seminar
    Stakos, Dimitrios A.
    Stamatelopoulos, Kimon
    Bampatsias, Dimitrios
    Sachse, Marco
    Zormpas, Eleftherios
    Vlachogiannis, Nikolaos I.
    Tual-Chalot, Simon
    Stellos, Konstantinos
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (08) : 952 - 967
  • [49] Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease
    Vander Zanden, Crystal M.
    Chi, Eva Y.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (01) : 68 - 73
  • [50] SHARPIN: Role in Finding NEMO and in Amyloid-Beta Clearance and Degradation (ABCD) Pathway in Alzheimer’s Disease?
    Dhanya Krishnan
    Ramsekhar N. Menon
    Srinivas Gopala
    Cellular and Molecular Neurobiology, 2022, 42 : 1267 - 1281